PDF(Pubmed)
Abstract：
Lowing blood lipid levels with probiotics has good application prospects. This study aimed to isolate probiotics with hypolipidemic efficacy from homemade na dish and investigate their mechanism of action. In vitro experiments were conducted to determine the cholesterol-lowering ability of five isolates, with results showing that Lactiplantibacillus plantarum N4 exhibited a high cholesterol-lowering rate of 50.27% and significant resistance to acid (87%), bile salt (51.97%), and pepsin (88.28%) in simulated gastrointestinal fluids, indicating promising application prospects for the use of probiotics in lowering blood lipids. The findings from the in vivo experiment demonstrated that the administration of N4 effectively attenuated lipid droplet accumulation and inflammatory cell infiltration in the body weight and liver of hyperlipidemic rats, leading to restoration of liver tissue morphology and structure, as well as improvement in lipid and liver biochemical parameters. 16S analysis indicated that the oral administration of N4 led to significant alterations in the relative abundance of various genera, including Sutterella, Bacteroides, Clostridium, and Ruminococcus, in the gut microbiota of hyperlipidemia rats. Additionally, fecal metabolomic analysis identified a total of 78 metabolites following N4 intervention, with carboxylic acids and their derivatives being the predominant compounds detected. The transcriptomic analysis revealed 156 genes with differential expression following N4 intervention, leading to the identification of 171 metabolic pathways through Kyoto Encyclopedia of Genes and Genomes enrichment analysis. Notably, the glutathione metabolism pathway, PPAR signaling pathway, and bile secretion pathway emerged as the primary enrichment pathways. The findings from a comprehensive multi-omics analysis indicate that N4 influences lipid metabolism and diminishes lipid levels in hyperlipidemic rats through modulation of fumaric acid and γ-aminobutyric acid concentrations, as well as glutathione and other metabolic pathways in the intestinal tract, derived from both the gut microbiota and the host liver. This research offers valuable insights into the therapeutic potential of probiotics for managing lipid metabolism disorders and their utilization in the development of functional foods.
摘要：
益生菌降低血脂水平具有良好的应用前景。本研究旨在从自制纳菜中分离具有降血脂功效的益生菌，并探讨其作用机制。进行了体外实验，以确定五个分离株的降胆固醇能力，结果表明，植物乳杆菌N4表现出50.27%的高胆固醇降低率和显著的耐酸(87%)，胆盐（51.97%），和胃蛋白酶（88.28%）在模拟胃肠液中，表明益生菌在降血脂方面具有广阔的应用前景。体内实验结果表明，N4的给药可有效减轻高脂血症大鼠体重和肝脏的脂滴积累和炎症细胞浸润，导致肝脏组织形态和结构的恢复，以及改善脂质和肝脏生化参数。16S分析表明，N4的口服给药导致各种属的相对丰度发生显着变化，包括Sutterilla,拟杆菌,梭菌属,和Ruminococus,在高脂血症大鼠的肠道菌群中。此外,粪便代谢组学分析在N4干预后确定了总共78种代谢物，羧酸及其衍生物是检测到的主要化合物。转录组学分析显示，在N4干预后，156个基因具有差异表达，导致通过京都基因百科全书和基因组富集分析鉴定171个代谢途径。值得注意的是,谷胱甘肽代谢途径，PPAR信号通路,胆汁分泌途径作为主要富集途径出现。综合的多组学分析结果表明，N4通过调节富马酸和γ-氨基丁酸浓度影响高脂血症大鼠的脂质代谢并降低脂质水平，以及谷胱甘肽和肠道中的其他代谢途径，来自肠道微生物群和宿主肝脏。这项研究为益生菌管理脂质代谢紊乱的治疗潜力及其在功能食品开发中的利用提供了有价值的见解。
